Oncogene addiction

被引：676

作者：

Weinstein, I. Bernard ^{[1
,2
]}

Joe, Andrew ^{[1
,2
]}

机构：

[1] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA

[2] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA

来源：

CANCER RESEARCH | 2008年 / 68卷 / 09期

关键词：

D O I：

10.1158/0008-5472.CAN-07-3293

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene. This phenomenon, called "oncogene addiction," provides a rationale for molecular targeted therapy. The efficacy of this strategy requires novel methods, including integrative genomics and systems biology, to identify the state of oncogene addiction (i.e., the "Achilles heel") in specific cancers. Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction.

引用

页码：3077 / 3080

页数：4

共 19 条

[1] Integrative genomic approaches identify IKBKE as a breast cancer oncogene [J].

Boehm, Jesse S. ;

Zhao, Jean J. ;

Yao, Jun ;

Kim, So Young ;

Firestein, Ron ;

Dunn, Ian F. ;

Sjostrom, Sarah K. ;

Garraway, Levi A. ;

Weremowicz, Stanislawa ;

Richardson, Andrea L. ;

Greulich, Heidi ;

Stewart, Carly J. ;

Mulvey, Laura A. ;

Shen, Rhine R. ;

Ambrogio, Lauren ;

Hirozane-Kishikawa, Tomoko ;

Hill, David E. ;

Vidal, Marc ;

Meyerson, Matthew ;

Grenier, Jennifer K. ;

Hinkle, Greg ;

Root, David E. ;

Roberts, Thomas M. ;

Lander, Eric S. ;

Polyak, Kornelia ;

Hahn, William C. .

CELL, 2007, 129 (06) :1065-1079

[2] Reversible tumorigenesis by MYC in hematopoietic lineages [J].

Felsher, DW ;

Bishop, JM .

MOLECULAR CELL, 1999, 4 (02) :199-207

[3] Lineage dependency and lineage-survival oncogenes in human cancer [J].

Garraway, Levi A. ;

Sellers, William R. .

NATURE REVIEWS CANCER, 2006, 6 (08) :593-602

[4] Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch [J].

Giuriato, Sylvie ;

Ryeom, Sandra ;

Fan, Alice C. ;

Bachireddy, Pavan ;

Lynch, Ryan C. ;

Rioth, Matthew J. ;

van Riggelen, Jan ;

Kopelman, Andrew M. ;

Passegue, Emmanuelle ;

Tang, Flora ;

Folkman, Judah ;

Felsher, Dean W. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (44) :16266-16271

[5] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[6] Patterns of somatic mutation in human cancer genomes [J].

Greenman, Christopher ;

Stephens, Philip ;

Smith, Raffaella ;

Dalgliesh, Gillian L. ;

Hunter, Christopher ;

Bignell, Graham ;

Davies, Helen ;

Teague, Jon ;

Butler, Adam ;

Edkins, Sarah ;

O'Meara, Sarah ;

Vastrik, Imre ;

Schmidt, Esther E. ;

Avis, Tim ;

Barthorpe, Syd ;

Bhamra, Gurpreet ;

Buck, Gemma ;

Choudhury, Bhudipa ;

Clements, Jody ;

Cole, Jennifer ;

Dicks, Ed ;

Forbes, Simon ;

Gray, Kris ;

Halliday, Kelly ;

Harrison, Rachel ;

Hills, Katy ;

Hinton, Jon ;

Jenkinson, Andy ;

Jones, David ;

Menzies, Andy ;

Mironenko, Tatiana ;

Perry, Janet ;

Raine, Keiran ;

Richardson, Dave ;

Shepherd, Rebecca ;

Small, Alexandra ;

Tofts, Calli ;

Varian, Jennifer ;

Webb, Tony ;

West, Sofie ;

Widaa, Sara ;

Yates, Andy ;

Cahill, Daniel P. ;

Louis, David N. ;

Goldstraw, Peter ;

Nicholson, Andrew G. ;

Brasseur, Francis ;

Looijenga, Leendert ;

Weber, Barbara L. ;

Chiew, Yoke-Eng .

NATURE, 2007, 446 (7132) :153-158

[7] The concept of synthetic lethality in the context of anticancer therapy [J].

Kaelin, WG .

NATURE REVIEWS CANCER, 2005, 5 (09) :689-698

[8] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[9] Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J].

Kwak, EL ;

Sordella, R ;

Bell, DW ;

Godin-Heymann, N ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Driscoll, DR ;

Fidias, P ;

Lynch, TJ ;

Rabindran, SK ;

McGinnis, JP ;

Wissner, A ;

Sharma, SV ;

Isselbacher, KJ ;

Settleman, J ;

Haber, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7665-7670

[10]

MELLINGHOFF IK, 2007, MOL PATHWAYS, V13, P378

← 1 2 →